CAMBRIDGE, Mass.--Millennium Pharmaceuticals here has appointed six scientists to its scientific advisory board, including Chairman Christopher Walsh, Frank Austen, Gerald Fink, Raju Kucherlapati, Eric Lander, and Harvey Lodish. Mark Levin, Millennium's CEO, commented, "The expertise of these six scientific leaders will further drive Millennium's high-throughput drug discovery platform towards our goal of creating therapeutic products." Millennium is a drug discovery company that makes widespread use of bioinformatics.
Walsh is the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology, and Austen is the Theodore Beveire Bayles Professor of Medicine, at the Harvard Medical School. Fink is director and a founding member of the Whitehead Institute for Biomedical Research. Kucherlapati, a founder of Millennium, is a director of the company and chairman of molecular genetics at the Albert Einstein College of Medi cine. Lander is a member of the White head Institute and director of the MIT Genome Center, and Lodish is a professor of biology at MIT and a founding member of the Whitehead Institute.